SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding? Gary C.W. Chan, Sydney C.W. Tang Kidney International Volume 93, Issue 1, Pages 22-24 (January 2018) DOI: 10.1016/j.kint.2017.07.008 Copyright © 2017 International Society of Nephrology Terms and Conditions
Figure 1 Potential mechanisms at play to maintain the blood pressure (BP)–lowering effect of empagliflozin despite reducing renal function. CKD, chronic kidney disease. Kidney International 2018 93, 22-24DOI: (10.1016/j.kint.2017.07.008) Copyright © 2017 International Society of Nephrology Terms and Conditions